Ronald A Lubet Selected Research

Urinary Bladder Neoplasms (Bladder Cancer)

1/2020	Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers.
9/2017	Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer.
2/2014	Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.
2/2014	Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.
7/2013	The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome.
5/2012	Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
2/2012	Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.
5/2011	Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.
9/2010	Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models.
4/2010	Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ronald A Lubet Research Topics

Disease

124	Neoplasms (Cancer) 10/2023 - 04/2002
57	Carcinogenesis 01/2022 - 06/2002
31	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2003
30	Breast Neoplasms (Breast Cancer) 10/2023 - 02/2004
17	Adenoma (Adenomas) 01/2023 - 06/2002
17	Body Weight (Weight, Body) 09/2017 - 12/2005
16	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 09/2004
11	Adenocarcinoma 11/2019 - 04/2002
11	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2019 - 03/2002
10	Carcinoma (Carcinomatosis) 11/2019 - 06/2002
9	Colonic Neoplasms (Colon Cancer) 01/2022 - 09/2002
7	Adenocarcinoma of Lung 10/2019 - 03/2002
5	Skin Neoplasms (Skin Cancer) 09/2012 - 05/2003
5	Prostatic Neoplasms (Prostate Cancer) 03/2010 - 09/2002
4	Inflammation (Inflammations) 12/2010 - 12/2002
3	Squamous Cell Carcinoma of Head and Neck 01/2015 - 01/2010
3	Mouth Neoplasms (Oral Cancer) 01/2015 - 01/2010
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2013 - 05/2006
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2014

Drug/Important Bio-Agent (IBA)

26	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2002
24	CarcinogensIBA 10/2023 - 08/2003
22	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 01/2021 - 02/2005
16	Bexarotene (LGD1069)FDA Link 01/2020 - 02/2005
13	RNA (Ribonucleic Acid)IBA 01/2022 - 09/2004
12	Budesonide (Pulmicort)FDA LinkGeneric 04/2019 - 07/2002
11	Benzo(a)pyreneIBA 06/2015 - 05/2003
10	Estrogen ReceptorsIBA 10/2023 - 10/2004
10	Naproxen (Naprosyn)FDA LinkGeneric 01/2022 - 11/2009
10	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2002
10	hydroxide ionIBA 01/2020 - 03/2005
9	Gefitinib (Iressa)FDA Link 01/2020 - 12/2006
9	vinyl carbamateIBA 09/2012 - 07/2002
8	VaccinesIBA 10/2023 - 12/2013
8	AzoxymethaneIBA 10/2023 - 02/2004
8	Messenger RNA (mRNA)IBA 09/2012 - 09/2002
8	SmokeIBA 01/2007 - 02/2003
7	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022 - 11/2009
7	Celecoxib (Celebrex)FDA Link 01/2022 - 05/2003
6	GlucocorticoidsIBA 10/2023 - 10/2004
6	tipifarnib (R115777)IBA 10/2023 - 05/2003
6	ErbB Receptors (EGF Receptor)IBA 01/2023 - 12/2006
6	Tamoxifen FDA LinkGeneric 01/2020 - 07/2006
6	NitrosaminesIBA 09/2017 - 09/2004
6	DNA (Deoxyribonucleic Acid)IBA 03/2007 - 02/2004
5	Eflornithine (Ornidyl)FDA Link 10/2023 - 12/2002
5	Retinoid X Receptors (Retinoid X Receptor)IBA 10/2023 - 06/2006
5	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2022 - 01/2008
5	Proliferating Cell Nuclear Antigen (PCNA)IBA 11/2019 - 07/2002
5	Caspase 3 (Caspase-3)IBA 11/2019 - 03/2007
5	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2019 - 02/2004
5	Lapatinib (GW572016)FDA Link 01/2019 - 08/2011
5	Pioglitazone (Actos)FDA Link 07/2017 - 11/2010
5	Sulindac (Copal)FDA LinkGeneric 02/2014 - 09/2002
5	TeaIBA 01/2014 - 02/2006
5	RetinoidsIBA 09/2012 - 09/2002
5	polyphenon EIBA 06/2010 - 01/2006
4	Farnesyltranstransferase (Farnesyltransferase)IBA 10/2023 - 05/2003
4	Aromatase InhibitorsIBA 10/2023 - 01/2008
4	vorozoleIBA 01/2020 - 04/2008
4	Insulin (Novolin)FDA Link 09/2017 - 10/2002
4	4-Nitroquinoline-1-oxide (4 Nitroquinoline 1 oxide)IBA 01/2015 - 06/2006
4	LigandsIBA 01/2013 - 08/2005
4	Piroxicam (Feldene)FDA LinkGeneric 01/2010 - 06/2002
4	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2010 - 12/2002
4	OligonucleotidesIBA 07/2006 - 02/2004
4	Alitretinoin FDA Link 06/2006 - 09/2002
3	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2022 - 02/2003
3	Protein Subunit VaccinesIBA 01/2022 - 10/2017
3	AntigensIBA 01/2021 - 12/2013
3	Peptides (Polypeptides)IBA 01/2021 - 11/2016
3	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 03/2015
3	Atorvastatin (Lipitor)FDA Link 01/2020 - 02/2009
3	Dinoprostone (PGE2)FDA Link 11/2019 - 12/2002
3	AerosolsIBA 10/2019 - 06/2009
3	Rosiglitazone (Avandia)FDA Link 01/2015 - 08/2005
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2015 - 11/2010
3	retinamideIBA 09/2012 - 02/2004
3	Estrogens (Estrogen)FDA Link 03/2012 - 07/2006
3	FlavonoidsIBA 01/2012 - 12/2010
3	Phosphotransferases (Kinase)IBA 11/2011 - 07/2006
3	AndrogensIBA 03/2010 - 01/2007
3	SurvivinIBA 03/2008 - 03/2005
3	ProstaglandinsIBA 03/2008 - 05/2003
3	TransferasesIBA 01/2007 - 04/2006
2	EnzymesIBA 10/2023 - 02/2003
2	Cyclooxygenase 1IBA 10/2023 - 01/2014
2	Immune Checkpoint ProteinsIBA 01/2022 - 01/2021
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2021 - 11/2010
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 05/2013
2	Cyclin D1IBA 01/2020 - 03/2008
2	CholesterolIBA 11/2019 - 10/2007
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2019 - 05/2011
2	MicroRNAs (MicroRNA)IBA 04/2019 - 02/2012
2	Insulin-Like PeptidesIBA 06/2015 - 10/2002
2	Sirolimus (Rapamycin)FDA Link 04/2015 - 01/2006
2	Drinking WaterIBA 01/2015 - 01/2006

Therapy/Procedure

44	Chemoprevention 01/2022 - 06/2002
15	Therapeutics 06/2015 - 05/2003
4	Oral Administration 11/2011 - 10/2004
3	Aftercare (After-Treatment) 04/2019 - 10/2002